Biote Appoints Mary J. Puncochar as Chief Commercial Officer
30 5월 2023 - 9:30PM
Business Wire
Ms. Puncochar to Drive Execution of Biote’s
Strategic Sales and Marketing Initiatives
biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a
leading solutions provider in preventive health care through the
delivery of personalized hormone therapy, today announced the
appointment of Mary J. Puncochar as Chief Commercial Officer. In
this role, Ms. Puncochar will lead Biote’s commercial initiatives
to expand the Company’s presence in the growing market for hormone
replacement therapy.
Ms. Puncochar joins Biote with more than 30 years of experience
in sales, tech-enabled marketing and management roles at leading
healthcare, pharmaceutical and medical device companies. Prior to
joining Biote, Ms. Puncochar served as Head of the U.S. region at
Ascensia Diabetes Care, a global diabetes care company, where she
achieved commercial success through the development and launch of
innovative solutions and precision tools aimed at helping consumers
more effectively manage their health.
“I am delighted to announce the appointment of Mary J. Puncochar
as Biote’s Chief Commercial Officer,” said Terry Weber, Biote Chief
Executive Officer. “Mary is a proven and dynamic leader who has
substantial experience in managing teams, driving profitable growth
and commercializing products aimed at enhancing patient health and
wellness. I believe Mary will be a tremendous asset to Biote as we
expand our geographic presence, build our relationships with
healthcare providers and continue to strengthen the Biote
brand.”
“It is an honor to join Biote and advance the company’s mission
of connecting healthcare providers and consumers to preventive
treatments that are transforming healthy aging. I am excited to
join Biote’s talented team during this time of growth and am eager
to drive adoption of the Biote Method,” Ms. Puncochar stated.
Ms. Puncochar began her career as a healthcare provider at the
University of Minnesota and has also held positions of increasing
responsibility at companies including Bayer, Columbia Park Medical
Group, InHome Services, and Honeywell.
About Biote
Biote is transforming healthy aging through innovative,
personalized hormone optimization therapies delivered by
Biote-certified medical providers. Biote trains practitioners how
to identify and treat early indicators of hormone-related aging
conditions, an underserved $7 billion global market, providing
affordable symptom relief for patients and driving clinic success
for practitioners.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Some of the forward-looking statements can be identified
by the use of forward-looking words. Statements that are not
historical in nature, including the words “may,” “can,” “should,”
“will,” “estimate,” “plan,” “project,” “forecast,” “intend,”
“expect,” “hope,” “anticipate,” “believe,” “seek,” “target,”
“continue,” “could,” “might,” “ongoing,” “potential,” “predict,”
“would” and other similar expressions, are intended to identify
forward-looking statements. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual results or developments to differ materially from
those expressed or implied by such forward-looking statements,
including but not limited to: the success of our dietary
supplements to attain significant market acceptance among clinics,
practitioners and their patients; our customers’ reliance on
certain third parties to support the manufacturing of bio-identical
hormones for prescribers; our and our customers’ sensitivity to
regulatory, economic, environmental and competitive conditions in
certain geographic regions; our ability to increase the use by
practitioners and clinics of the Biote Method at the rate that we
anticipate or at all; our ability to grow our business; the
significant competition we face in our industry; our limited
operating history; our ability to protect our intellectual
property; the heavy regulatory oversight in our industry; changes
in applicable laws or regulations; the inability to profitably
expand in existing markets and into new markets; the possibility
that we may be adversely impacted by other economic, business
and/or competitive factors, including recent bank failures; and
future exchange and interest rates. The foregoing list of factors
is not exhaustive. You should carefully consider the risks and
uncertainties described in the “Risk Factors” section of the
Biote’s Quarterly Report on Form 10-Q for the fiscal quarter ended
March 31, 2023 and other documents filed by Biote from time to time
with the Securities and Exchange Commission. These filings identify
and address other important risks and uncertainties that could
cause actual events and results to differ materially from those
contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Biote assumes no obligation and does not intend to update or
revise these forward-looking statements, whether as a result of new
information, future events, or otherwise. Biote does not give any
assurance that it will achieve its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230530005165/en/
Investor Relations: Eric Prouty AdvisIRy Partners
eric.prouty@advisiry.com
Media: Press@biote.com
Biote (NASDAQ:BTMD)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Biote (NASDAQ:BTMD)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024